Caption Management, LLC Arbutus Biopharma Corp Transaction History

Caption Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $67,709 - $101,765	40,065 Added 1500.0%	42,736 $106,000
Q3 2023 Nov 14, 2023	BUY	$1.9 - $2.27 $5,074 - $6,063	2,671 New	2,671 $5,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $30,972 - $46,215	16,216 Added 48.0%	50,000 $116,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $31,990 - $49,006	-17,016 Reduced 33.5%	33,784 $64,000
Q2 2022 Aug 15, 2022	BUY	$1.98 - $3.17 $62,805 - $100,552	31,720 Added 166.25%	50,800 $138,000
Q1 2022 May 13, 2022	BUY	$2.42 - $3.98 $9,638 - $15,852	3,983 Added 26.38%	19,080 $58,000
Q4 2021 Feb 11, 2022	BUY	$3.11 - $4.61 $25,498 - $37,797	8,199 Added 118.86%	15,097 $59,000
Q3 2021 Nov 12, 2021	SELL	$2.65 - $4.62 $84,275 - $146,925	-31,802 Reduced 82.18%	6,898 $30,000
Q2 2021 Aug 16, 2021	BUY	$2.5 - $3.51 $96,750 - $135,837	38,700 New	38,700 $118,000
Q1 2019 May 14, 2019	SELL	$3.41 - $4.57 $17,050 - $22,850	-5,000 Closed	0 $0
Q4 2018 Jan 30, 2019	BUY	$3.5 - $9.66 $17,500 - $48,300	5,000 New	5,000 $20,000

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.